Anaphylaxis is a potentially life-threatening allergic reaction that may 
cause severe swelling, respiratory compromise (dyspnea, wheezing), hypotension, 
and possibly death. There are multiple ways to treat someone suffering from 
anaphylaxis. The most common course of treatment is the use of epinephrine.
Treatment of anaphylaxis using epinephrine 
and available products
Epinephrine is the first and most important treatment for anaphylactic 
reactions because it stimulates the alpha- and beta-adrenergic receptors, which 
increases vasoconstriction and bronchodilation.1 Epinephrine pens 
are indicated for the emergency treatment of allergic reactions (type I), 
including anaphylaxis, which may result from allergic reactions to insect 
stings, biting insects, foods, drugs, sera, diagnostic testing substances, and 
other allergens, as well as idiopathic anaphylaxis or exercise-induced 
anaphylaxis. There are multiple epinephrine products currently available on the 
market in 0.3 mg and 0.15 mg doses that are indicated for use as follows:
- 0.3 mg: For adults and children over 30 kg;
- 0.15 mg: For children between 15 kg and 29 kg.
The chart below shows the available epinephrine products, the formulary 
tier, and if prior authorization is required.
| Epinephrine product | Formulary 
tier | Prior authorization required? | 
|---|
| EpiPen® | Preferred 
brand | Not required | 
| Epinephrine (generic for EpiPen®)* | Generic | Not required | 
| Adrenaclick® | Non-Preferred brand | Required | 
| Epinephrine (generic for Adrenaclick®)* | Generic | Not required | 
| Auvi-Q® | Non-Preferred 
brand | Required | 
*If you wish to substitute the generic version, where 
available, you must note that substitution is allowed or write the chemical 
compound, epinephrine, on the prescription.
For additional information about pharmacy policies and programs, visit our 
website.
 
1Simmons, F 
Estelle, et al. ?World Allergy Organization Guidelines for the Assessment and 
Management of Anaphylaxis.? World Allergy Organization Journal. Available from: www.waojournal.org/content/4/2/13.